SKYE
Skye Bioscience, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.42
P/S
0.00
EV/EBITDA
0.00
DCF Value
$0.10
FCF Yield
-38688.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-143.6%
ROA
-197.5%
ROIC
-286.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-14.4M | $-0.36 |
| FY 2025 | $0.00 | $-55.9M | $-1.41 |
| Q3 2025 | $0.00 | $-12.8M | $-0.32 |
| Q2 2025 | $0.00 | $-17.6M | $-0.44 |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$12.00
Target (Median)
$15.00
Target Range
$2.00 - $21.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.87
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.